主要文件

查看所有文档

SML3638

Ceftobiprole

Name: Ceftobiprole
Brand: SIGMA

≥95% (HPLC), Cell wall synthesis inhibitor, powder

别名:

(6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-ylidene)- 2-nitroso-1-oxoethyl]amino]-8-oxo-3-[(E)-[2-oxo-1-[(3R)- 3-pyrrolidinyl]-3-pyrrolidinylidene]methyl]-5-thia-1- azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, BAL 9141, BAL 9141-000, Ro 63-9141

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₀H₂₂N₈O₆S₂

化学文摘社编号:

209467-52-7

分子量:

534.57

UNSPSC Code:

51111800

NACRES:

NA.25

MDL number:

MFCD25976436

Assay:

≥95% (HPLC)

Form:

powder

Quality level:

100

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

Ceftobiprole, ≥95% (HPLC)

Quality Level

100

assay

≥95% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear (Acidified)

storage temp.

-10 to -25°C

SMILES string

[s]1nc(nc1N)C(N=O)C(=O)N[C@H]2[C@H]3SCC(=C(N3C2=O)C(=O)O)\C=C4/CCN(C/4=O)[C@H]5CNCC5

InChI

1S/C20H22N8O6S2/c21-20-24-14(26-36-20)11(25-34)15(29)23-12-17(31)28-13(19(32)33)9(7-35-18(12)28)5-8-2-4-27(16(8)30)10-1-3-22-6-10/h5,10-12,18,22H,1-4,6-7H2,(H,23,29)(H,32,33)(H2,21,24,26)/b8-5+/t10-,11?,12-,18-/m1/s1

InChI key

XLHWFEHWWUCKOL-ADPMQJGOSA-N

说明

Biochem/physiol Actions

Broad-spectrum cephalosporin active against MRSA

Ceftobiprole is a fifth generation broad spectrum cephalosporin that is active against many resistant bacterial strains including methicillin-resistant Staphylococcus aureus (MRSA). Ceftobiprole inhabits PBP1 (penicillin-binding protein 1), PBP2 and ß-lactam resistance determinant PBP2a.

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

涉药品监管产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Impact of PBP4 Alterations on ?-Lactam Resistance and Ceftobiprole Non-Susceptibility Among Enterococcus faecalis Clinical Isolates

Lazzaro LM, Cassisi M, Stefani S, Campanile F

Frontiers in Cellular and Infection Microbiology, 11, 816657-816657 (2022)

Activity of ceftobiprole against Staphylococcus spec. isolates derived from foreign body associated infections.

Gunnar T R Hischebeth et al.

Diagnostic microbiology and infectious disease, 91(2), 175-178 (2018-02-18)

Antibiotic therapy is essential in foreign body associated infections. The treatment regime should aim at high tissue concentrations, high bioavailability, high biofilm penetration and good tolerance. We investigated whether the new cephalosporin ceftobiprole is active against clinical isolates from musculoskeletal

Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013-2015.

Anne Santerre Henriksen et al.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 37(9), 1653-1659 (2018-06-08)

Coagulase-negative staphylococci (CoNS) are a significant cause of bacteraemia, the treatment of which is becoming increasingly complex due to the emergence of multidrug-resistant strains. This study aimed to evaluate the in vitro activity of ceftobiprole, an advanced-generation cephalosporin, as compared

全球贸易项目编号

货号	GTIN
SML3638-25MG	04065269401766
SML3638-5MG	04065269401773